GH
Guardant Health, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$172.82
−1.25%Nov 3, 2026, 13:27 UTC
Guardant Health granted Co-Chief Executive Officers Helmy Eltoukhy and AmirAli Talasaz each 465,413 performance-based restricted stock units at target, effective November 2, 2026.
Oct 20, 2026, 13:02 UTC
Guardant Health announced that it and its research collaborators will present 25 abstracts, including five rapid oral presentations, at the Guardant Health, Inc. on liquid biopsy research across lung, colorectal and gastric cancers.
Source:Oct 8, 2026, 20:05 UTC
Guardant Health announced that it will report its third-quarter 2026 financial results after market close on November 5, 2026.
Source:Oct 5, 2026, 15:27 UTC
Guardant Health announced that Cancer Research Communications published results from the COSMOS-MEL01 study, the first prospective multicenter evaluation of its tissue-free epigenomic Guardant Reveal blood test for molecular residual disease detection and recurrence monitoring in melanoma patients.
Source:Sep 14, 2026, 20:05 UTC
EviCore by Evernorth added Guardant Health's Shield blood test for colorectal cancer screening to its clinical guidelines, effective January 1, 2027.
Source:Aug 25, 2026, 10:01 UTC
Callan Family Office LLC acquired a new stake in Guardant Health, Inc. by purchasing 6,080 shares valued at approximately $912,000 in the second quarter, as disclosed in its 13F filing.
Source:Aug 24, 2026, 21:53 UTC
On August 24, 2026, Guardant Health Inc's shares fell 4.4% to $163.18.
Source:Aug 24, 2026, 15:58 UTC
A Delaware federal judge finalized a ruling ordering Guardant Health to pay over $245.2 million to TwinStrand Biosciences and the University of Washington for willfully infringing two Duplex Sequencing patents, cementing a November 2023 jury verdict.
Source:Aug 14, 2026, 05:04 UTC
Guardant Health announced planned product launches in its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference.
Source:Aug 6, 2026, 21:38 UTC
Guardant Health Inc shares declined 3.4% on August 6, 2026, trading at $157.58.
Source:Aug 6, 2026, 01:36 UTC
Manulife Hong Kong and Macau partnered with Guardant Health to exclusively offer multiple cancer detection services to eligible customers in Hong Kong.
Source:Jul 31, 2026, 15:57 UTC
Zydus Lifesciences signed a Memorandum of Understanding with Apollo Hospitals to expand access to Guardant Health's Shield Multi-Cancer Detection test in India.
Source:Jul 31, 2026, 00:31 UTC
Guardant Health reported its Q2 2026 financial results, with a loss of $0.42 per share, missing the Zacks Consensus Estimate of a loss of $0.40 per share, compared to a loss of $0.44 per share a year ago.
Source:Jun 22, 2026, 11:53 UTC
The U.S. Food and Drug Administration approved Guardant360 Liquid CDx, a liquid biopsy panel developed by Guardant Health, Inc.
Source:Jun 11, 2026, 12:05 UTC
The FDA approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS.
Source: